off-label use of glp-1 agonists for obesity in 2016 Prevalence and interest using glucagon-like peptide-1 receptor weight loss: a population study in Great Britain | BMC Medicine Emerging Role of GLP-1 Agonists
Description
Tang-Christensen M, Larsen PJ, Gke R, Fink-Jensen A, Jessop DS, Mller M, et al
National Institute of Clinical Excellence
In August 2024, Eli Lilly & Company announced the positive outcomes of the SURMOUNT-1 trial, indicating that Tirzepatide (marketed as Zepbound and Mounjaro) decreased the risk of developing type 2 diabetes by 94% in individuals with prediabetes, obesity, or overweight
c in patients with concurrent T2DM
The results of a recent meta-analysis show that GLP-1RA treatment leads to higher occurrences of AV, prompting concern about their comprehensive skin-related side effects [68]
